💊 ADHD Medication Diversion Misuse Risk Simulator

Stimulant Therapy for Diagnosed ADHD

A clinician prescribes a stimulant after a structured ADHD evaluation.

• ~4.4%: US adults with ADHD (diagnosed, lifetime prevalence)
• Rising: College-age Rx growth (stimulant prescriptions 18-25)
• 2 classes: First-line stimulants (methylphenidate, amphetamine)
• II: Schedule (controlled substance, DEA)

What legitimate treatment looks like

Diagnosis, dosing, and follow-up under clinical supervision.

Why stimulants are controlled

Schedule II status reflects real abuse and dependence potential.

Peer Requests and the Diversion Pathway

Diversion means sharing or selling prescribed pills to someone else.

• ~1 in 5: College misuse exposure (students asked to share/sell)
• Exam periods: Peak risk window (highest peer request rate)
• Friends/peers: Common source (not illicit dealers)
• Felony-level: Legal risk (unauthorized distribution)

Social pressure drives diversion

Requests from roommates and classmates are the main pathway.

Campus prevalence patterns

Diversion clusters around finals, papers, and high-stakes exams.

Off-Label Use for Perceived Academic Edge

Misuse means taking more than prescribed, or using without a diagnosis.

• Common myth: Non-ADHD "study aid" use (no proven cognitive benefit)
• Elevated: Overdose risk (cardiac and psychiatric effects)
• Crush/snort: Route escalation (defeats slow-release design)
• Present: Dependence potential (with repeated high-dose use)

The performance-enhancement myth

Non-prescribed use rarely improves focus in people without ADHD.

Physical and mental health risks

Higher doses raise cardiovascular and psychiatric risk sharply.

Formulation, Monitoring, Storage, and Education

Layered safeguards each blunt a different part of the risk pathway.

• Harder to misuse: Extended-release effect (resists crushing/snorting)
• PDMP: Monitoring programs (flags unusual refill patterns)
• Lockbox: Secure storage (blocks casual household access)
• Lowers sharing: Education impact (patients informed of risks)

Extended-release formulations

Slow-release matrices are harder to convert into a fast high.

Monitoring, storage, and education combined

Layering safeguards closes gaps that any single measure misses.

Reduced Risk, Preserved Legitimate Access

Combined safeguards cut diversion and misuse without denying care.

• Meaningful: Risk reduction (modeled) (with all 4 safeguards active)
• Preserved: Patient access (treatment continuity maintained)
• Layered defense: Best practice (no single safeguard suffices)
• Balance: Goal (safety without overrestriction)

Why layered safeguards work

Each safeguard blocks a different point in the risk pathway.

Sustaining safe, legitimate treatment

Ongoing monitoring keeps therapy safe without limiting real need.

Safeguards aim to reduce diversion and misuse while keeping treatment accessible for patients who need it.